Pascal and Francis Bibliographic Databases

Help

Search results

Your search

jo.\*:(%22Nutrition and cancer%22)

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Origin

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 180657

  • Page / 7227
Export

Selection :

  • and

A new index comparable to BED for evaluating the biological efficacy of hypofractionated radiotherapy schemes on early stage non-small cell lung cancer: Analysis of data from the literatureCHENG KONG; GUO, Wen-Jie; ZHA, Wen-Wu et al.Lung cancer. 2014, Vol 84, Num 1, pp 7-12, issn 0169-5002, 6 p.Article

A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: Re-evaluation of EGFR gene status (NEJ006/TCOG0903)MATSUMOTO, Yoshifumi; MAEMONDO, Makoto; USUI, Kazuhiro et al.Lung cancer. 2014, Vol 86, Num 2, pp 195-200, issn 0169-5002, 6 p.Article

A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901)MURAKAMI, Haruyasu; YAMAMOTO, Nobuyuki; SATOUCHI, Miyako et al.Lung cancer. 2014, Vol 84, Num 1, pp 67-72, issn 0169-5002, 6 p.Article

A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapyWEISS, Jared M; VILLARUZ, Liza C; SOCINSKI, Mark A et al.Lung cancer. 2014, Vol 86, Num 2, pp 288-290, issn 0169-5002, 3 p.Article

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)XINGSHENG HU; BAOHUI HAN; MEINA WU et al.Lung cancer. 2014, Vol 86, Num 2, pp 207-212, issn 0169-5002, 6 p.Article

Bone metastasis, skeletal-related events, and mortality in lung cancer patients: A Danish population-based cohort studyCETIN, Karynsa; CHRISTIANSEN, Christian Fynbo; JACOBSEN, Jacob Bonde et al.Lung cancer. 2014, Vol 86, Num 2, pp 247-254, issn 0169-5002, 8 p.Article

Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatmentKIM, Hye-Ryoun; JAE CHOL LEE; RYU, Jeong-Seon et al.Lung cancer. 2014, Vol 83, Num 2, pp 252-258, issn 0169-5002, 7 p.Article

Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancerPALLAUD, Celine; RECK, Martin; JUHASZ, Erzsebet et al.Lung cancer. 2014, Vol 86, Num 1, pp 67-72, issn 0169-5002, 6 p.Article

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)TISEO, Marcello; ANDREOLI, Roberta; MUTTI, Antonio et al.Lung cancer. 2014, Vol 83, Num 2, pp 265-271, issn 0169-5002, 7 p.Article

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?MACERELLI, M; CARAMELLA, C; PIGNON, J. P et al.Lung cancer. 2014, Vol 83, Num 3, pp 383-388, issn 0169-5002, 6 p.Article

Dramatic response to high-dose icotinib in a lung adenocarcinoma patient after erlotinib failureYIN GUAN; HONG ZHAO; JING MENG et al.Lung cancer. 2014, Vol 83, Num 2, pp 305-307, issn 0169-5002, 3 p.Article

EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: A meta-analysisQIONG ZHANG; DAI, Hong-Hai; DONG, Hong-Yun et al.Lung cancer. 2014, Vol 85, Num 3, pp 339-345, issn 0169-5002, 7 p.Article

Efficacy and safety of gefitinib during pregnancy: Case report and literature reviewGIL, S; GOETGHELUCK, J; PACI, A et al.Lung cancer. 2014, Vol 85, Num 3, pp 481-484, issn 0169-5002, 4 p.Article

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trialsSCAGLIOTTI, G. V; GRIDELLI, C; CHOUAKI, N et al.Lung cancer. 2014, Vol 85, Num 3, pp 408-414, issn 0169-5002, 7 p.Article

Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancerWU, Yi-Long; SHUN LU; XIN WANG et al.Lung cancer. 2014, Vol 85, Num 3, pp 401-407, issn 0169-5002, 7 p.Article

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trialsNING ZHAO; ZHANG, Xu-Chao; YAN, Hong-Hong et al.Lung cancer. 2014, Vol 85, Num 1, pp 66-73, issn 0169-5002, 8 p.Article

Genetic profiling of thymic carcinoma using targeted next-generation sequencingSHITARA, Masayuki; OKUDA, Katsuhiro; SUZUKI, Ayumi et al.Lung cancer. 2014, Vol 86, Num 2, pp 174-179, issn 0169-5002, 6 p.Article

Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancerTAI SUN PARK; KIM, Hye-Ryoun; JUNGMIN JO et al.Lung cancer. 2014, Vol 86, Num 2, pp 262-267, issn 0169-5002, 6 p.Article

Identification of actionable mutations in malignant pleural mesotheliomaSHUKUYA, Takehito; SERIZAWA, Masakuni; NAITO, Tateaki et al.Lung cancer. 2014, Vol 86, Num 1, pp 35-40, issn 0169-5002, 6 p.Article

Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study)TOFFART, Anne-Claire; TIMSIT, Jean-Francois; ROMAND, Philippe et al.Lung cancer. 2014, Vol 83, Num 2, pp 182-188, issn 0169-5002, 7 p.Article

Is there a relationship between the presence of lung mucosa preinvasive lesions and lung cancer incidence? Influence of tobacco consumptionCLEMENT-DUCHENE, Christelle; ALLA, François; GAUCHOTTE, Guillaume et al.Lung cancer. 2014, Vol 84, Num 2, pp 134-138, issn 0169-5002, 5 p.Article

Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLCBAHCE, I; VOS, C. G; DICKHOFF, C et al.Lung cancer. 2014, Vol 85, Num 2, pp 205-212, issn 0169-5002, 8 p.Article

Methylation and expression profiles of MGMT gene in thymic epithelial tumorsMOKHTAR, Mohamed; KONDO, Kazuya; YOSHIDA, Mitsuteru et al.Lung cancer. 2014, Vol 83, Num 2, pp 279-287, issn 0169-5002, 9 p.Article

NF-κB protein expression associates with 18F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolismNAIR, Viswam S; GEVAERT, Olivier; DAVIDZON, Guido et al.Lung cancer. 2014, Vol 83, Num 2, pp 189-196, issn 0169-5002, 8 p.Article

Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patientsPIRCHER, Andreas; GAMERITH, Gabriele; WOLF, Anna Maria et al.Lung cancer. 2014, Vol 85, Num 1, pp 81-87, issn 0169-5002, 7 p.Article

  • Page / 7227